~~<i id='42C1D30B69'><strike id='42C1D30B69'><tt id='42C1D30B69'><pre id='42C1D30B69'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：entertainment 2025-09-29 20:44:38 Page View：7

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Brain 'hot spot' may explain why African Americans feel greater pain
Next article： Peter Hotez and the public health issue of online harassment

focus

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Connecting traumatic brain injury and domestic violence

CTbrainofapatientwithtraumaticbraininjuryshowingsubarachnoidhemorrhage.AdobeTraumaticbraininjury,lon

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

JustinSullivan/GettyImagesWhenpeoplemisrepresentfactsontherecord,journalistsareinatoughspot—especial